Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes

Diabetes Care

Volumn 31, Issue 9, 2008, Pages 1723-1728

  Rosenstock, Julio ^a   Cefalu, William T ^b   Hollander, Priscilla A ^c   Belanger, Andre ^d   Eliaschewitz, Freddy G ^e   Gross, Jorge L ^f   Klioze, Solomon S ^g   St Aubin, Lisa B ^g   Foyt, Howard ^h   Ogawa, Masayo ^h   Duggan, William T ^g  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Cité de la Santé Hospital   (Canada)

^e HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT GAIN; BLOOD; DIFFUSION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; RACE; SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; CARBON MONOXIDE; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DIFFUSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; RESPIRATORY FUNCTION TESTS; SAFETY; TREATMENT OUTCOME;

EID: 56149114105     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0159     Document Type: Article

References (28)

1. DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS, Exubera Phase III Study Group: Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 28:1922-1928, 2005
2. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering K, Hendler R, Lan S-P, Cefalu WT: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann lntern Med 143:549-558, 2005
3. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M: An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 29:1282-1287, 2006
4. Barnett AH, Dreyer M, Lange P, Ser- darevic-Pehar M: An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 29:1818-1825, 2006
5. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M, Exubera Phase 3 Study Group: Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. lnt J Clin Pract 61:1614-1625, 2007
6. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson J-L, Levin SR, for the Exubera Phase 3 Study Group: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2356-2362, 2004
7. Jensen RL, Teeter JG, England RD, Howell HM, White HJ, Pickering EH, Crapo RO: Sources of long-term variability in measurements of lung function: implications for interpretation and clinical trial design. Chest 132:396-402, 2007
8. Jensen RL, Teeter JG, England RD, Howell HM, White HJ, Pickering EH, Crapo RO: Instrument accuracy and reproducibility in measurements of pulmonary function. Chest 132:388-395, 2007
9. Maclntyre N: Finding signals amidst the noise in pulmonary function testing. Chest 132:367-368, 2007
10. Wise RA, Teeter JG, Jensen RL, England RD, Schwartz PF, Ahrens RC, MacIntyre NR, Riese RJ, Crapo RO: Standardization of the single-breath diffusing capacity in a Multicenter Clinical Trial. Chest 132: 1191-1197, 2007
11. Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159:179-187, 1999
12. Crapo RO, Morris AH, Clayton PD, Nixon CR: Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir 18:419-425, 1982
13. Miller A, Thornton JC, Warshaw R, Anderson H, Teirstein SA, Selikoff IJ: Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Am Rev Respir Dis 127:270-277, 1983
14. American Thoracic Society: Standardization of Spirometry, 1994 update. Am J Respir Crit Care Med 152:1107-1136, 1995
15. American Thoracic Society: Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 152:2185-2198, 1995
16. Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea: contents, interobserver agreement, and physiologic correlations of two new clinical indices. Chest 85:751-758, 1984
17. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W, Inhaled Human Insulin Type 1 Diabetes Study Group: Two year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes mellitus. Diabetes Care 30:579-585, 2007
18. Fletcher C, Peto R: The natural history of chronic airflow obstruction. BMJ 1:16451648, 1977
19. Dockery DW, Ware JH, Ferris BG Jr, Glicksberg DS, Fay ME, Spiro A 3rd, Speizer FE: Distribution of forced expiratory volume in one second and forced vital capacity in healthy, white, adult, never-smokers in six U.S. cities. Am Rev Respir Dis 131:511-520, 1985
20. Ryan G, Knuiman M, Divitini ML, Ryan G, Bartholomew HC, Musk AW: Decline in lung function and mortality: the Bus- selton Health Study. J Epidemiol Community Health 53:230-234, 1999
21. Davis WA, Knuiman M, Kendall P, Grande V, Davis TME: Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 27:752-757, 2004
22. Weynand B, Jonckheere A, Frans A, Rahier J: Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 66:14-19, 1999
23. FarinaJ, Furio V, Fernandez-Acenero MJ, Muzas MA: Nodular fibrosis of the lung in diabetes mellitus. Virchows Arch 427:61-63, 1995
24. Hisa CC, Raskin P: Lung function changes related to diabetes mellitus. Diabetes Technol Ther 9 (Suppl. 1):S73-S82, 2007
25. Witek TJ, Mahler DA: Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 56: 248-255, 2003
26. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A: Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exu- bera) trials and a two-year extension trial. J Clin Endocrinol Metab 90:3287-3293, 2005
27. Heise T, Bott S, Tusek C, Stephan J-A, Kawabata T, Finco-Kent D, Liu C, Krasner A: The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 28;2161-69, 2005
28. Teeter JG, Riese RJ: Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 173:1194-1200, 2006